Global Global Cancer Vaccines Market Size, Share, Growth & Report 2022-2027

Byimarcsuraj

IMARC Group has recently released a new research study “Cancer Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.

What Are The Growth Prospects Of The Cancer Vaccines Industry?

The global cancer vaccines market size reached US$ 5.43 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 10.72 Billion by 2027, exhibiting a growth rate (CAGR) of 11.70% during 2022-2027.

What is a Cancer Vaccines ?

Cancer refers to a malignant tumor caused by the uncontrollable growth of abnormal cells in the body. It can be treated through the use of numerous medications and vaccines. Among these, vaccinations are broadly classified into preventive and therapeutic. Preventive cancer vaccines are deployed to eliminate the tumor generated by oncovirus and protect from human papillomavirus (HPV), whereas therapeutic vaccinations aid in stimulating the individual adaptive immune systems by using tumor antigens. Presently, these vaccines are commercially available in varying types, such as antigen, dendritic cells, and anti-idiotype.

What Are The Key Factors Driving In The Cancer Vaccines Market: 

The growing prevalence of the tumor, on account of the increasing consumption of tobacco-based products and evolving lifestyles of the masses, is primarily augmenting the cancer vaccines market. Furthermore, the launch of favorable initiatives undertaken by the government bodies of several countries for introducing novel cancer vaccinations and various investments in the field of recombinant viral immunization are positively influencing the global market.

Request For Sample Report: https://www.imarcgroup.com/cancer-vaccines-market/requestsample

Apart from this, the rising utilization of United States Food and Drug Administration (US FDA) approved boosters, including the human papillomavirus vaccine (HPV) and hepatitis B vaccine (HBV), to reduce the risk of certain types of cancer, such as a liver tumor, is acting as another significant growth-inducing factor. Moreover, the inflating technological advancements that focus on the development of effective and specific cancer treatments are also bolstering the market growth. Besides this, the expanding healthcare infrastructure, the growing geriatric population, who are susceptible to numerous chronic ailments, including cancer, and the increasing consumer awareness regarding the symptoms and the available therapy options are expected to drive the cancer vaccines market in the coming years.

Who Are The Key Factors Driving In The Cancer Vaccines Market?

Anixa Biosciences Inc., Dendreon Pharmaceuticals LLC, Dynavax Technologies Corporation, GSK plc, Merck & Co. Inc., Moderna Inc., OSE Immunotherapeutics, Providence Therapeutics, Sanofi S.A., UbiVac Inc. and Vaccitech plc. 

Report Segmentation:

The report has been segmented the market into following categories:

Breakup by Type:

  • Preventive Cancer Vaccines
  • Therapeutic Cancer Vaccines

Breakup by Technology:

  • Dendritic Cells Cancer Vaccines
  • Recombinant Cancer Vaccines
  • Antigen/Adjuvant Cancer Vaccines
  • Viral Vector and DNA Cancer Vaccines
  • Whole-cell Cancer Vaccines

Breakup by Indication:

  • Cervical Cancer
  • Prostate Cancer
  • Others

Breakup by End User:

  • Pediatrics
  • Adults 

By Geography:

  • North America (United States, Canada)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Others)
  • Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

Ask An Analyst: https://www.imarcgroup.com/request?type=report&id=5901&flag=C

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Services Private Limited.

30 N Gould St Ste R

Sheridan, WY 82801 USA – Wyoming

Email: Sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

Americas:- +1 631 791 1145 |

Africa and Europe :- +44-702-409-7331 |

Asia: +91-120-433-0800, +91-120-433-0800